Evidence map›Paper›PMID 36147518›Full record

ArticleInternational journal of pharmaceutics: X2022

Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.

Sahar Eljack, Stephanie David, Areeg Faggad, Igor Chourpa, Emilie Allard-Vannier

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Targeted Folate-Chitosan Nanoformulations of Quercetin andPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sahar EljackEA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, Tours, France.
Stephanie DavidEA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, Tours, France.
Areeg FaggadDepartment of Molecular Biology, National Cancer Institute, University of Gezira (NCI-UG), Wadmedani, Sudan.
Igor ChourpaEA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, Tours, France.
Emilie Allard-VannierEA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, Tours, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoresistance and hence the consequent treatment failure is considerably challenging in clinical cancer therapeutics. The understanding of the genetic variations in chemoresistance acquisition encouraged the use of gene modulatory approaches to restore anti-cancer drug efficacy. Many smart nanoparticles are designed and optimized to mediate combinational therapy between nucleic acid and anti-cancer drugs. This review aims to define a rational design of such co-loaded nanocarriers with the aim of chemoresistance reversal at various cellular levels to improve the therapeutic outcome of anticancer treatment. Going through the principles of therapeutics loading, physicochemical characteristics tuning, and different nanocarrier modifications, also looking at combination effectiveness on chemosensitivity restoration. Up to now, these emerging nanocarriers are in development status but are expected to introduce outstanding outcomes.

Indexed as

5-FU, 5-FlurouracilABCB, ATP Binding Cassette Subfamily B MemberAIF, Apoptosis-inducing factorAKT, Serine/threonine kinaseAnti-cancer drugsASGPR, The asialoglycoprotein receptorASO, Antisense oligonucleotidesBak, Bcl2-antagonist/killerBax, Bcl-2-associated X protein apoptotic activatorBBB, Blood-brain barrierBcl-2, B-cell lymphoma 2Bcl-xl, B-cell lymphoma-extra largeBCRP, Breast cancer-resistant proteinCAV-1, Caveolin 1CDK, Cyclin-dependent kinaseChemoresistance reversalChNPs, Chitosan nanoparticlesCI, Combination indexCisPt, CisplatinCMD, Carboxymethyl dextranc-Myc, C-Master regulator of cell cycle entry, proliferative and metabolismCombination therapyCPT, CamptothecinCSCs, Cancer stem cellsCT, The computed tomographyDMSO, Dimethyl sulfoxideDOPE, DioleoylphosphatidylethanolamineDOTAP, 1,2-Dioleoyl-3-trimethylammonium propaneDOX, DoxorubicinDSPE, 1,2-Distearoyl-sn-glycerol-3-phosphoethanolamineDTX, DocetaxelEC50, The half maximal effective concentrationE-CAD, E-cadherinEGFR, Epidermal growth factor receptorEPR, The enhanced permeability and retentionERK, Extracellular regulated kinaseEZH2, Enhancer Of Zeste 2 Polycomb Repressive Complex 2 SubunitFAK, Focal adhesion kinaseFRα, Folate receptor-αGalNAc, N-acetylgalactosamineGEM, GemcitabineGnRH, Gonadotropin-releasing hormoneGSH, GlutathioneH1F1, Hypoxia-inducible factor 1HRAS, GTPase HRas enzymeIC50, The half-maximal inhibitory concentrationIL-17B, Interleukin 17BILK, Integrin-linked kinaseKras, Kirsten rat sarcoma GTPase enzymeLDL, Low-density lipoproteinLHRH, Luteinizing hormone-releasing hormoneLHSSG2C, Ditetradecyl 2-(4-(2-(2-(2-(2-(2,6-diaminohexanamido)-3-(1H-imidazole-4-yl) propanamido) ethyl) disulfanyl) ethylamino)-4-oxobutanamido) pentanedioateLRP, Lung resistant proteinMAPK, Mitogen-activated protein kinaseMDM, Mixed dendrimer micellesMDR, Multidrug-resistantmiRNA, Micro ribonucleic acidMRI, Magnetic resonance imagesMSNRs, Mesoporous silica nanorodsMTDH, MetadherinMTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromideMVP, Major vault proteinNanoparticlesNF-κB, Nuclear factor-kappa light chain enhancer of activated B cellsNotch-1, Notch homolog 1, translocation-associatedNucleic acidsOEI, OligoethylenimineORF, Open reading frameOxaPt, Oxaliplatinp27Kip1, Cell cycle inhibitorPAH, Poly (acrylhydrazine)pAKT, Phosphatidylinositol 3-kinase and Protein KinasePAMAM, PolyamidoaminePBS, Phosphate Buffered SalinePDMAPMA, Poly (3-dimethylaminopropyl methacrylamide)pDNA, Plasmid deoxyribonucleic acidPDX, Patient-derived xenograftPEG, Polyethylene glycolPEI, PolyethyleneimineP-gp, P-glycoproteinPI3-kinase, Phosphatidylinositol 3′-kinasePLA, Polylactic acidPLGA, Poly (lactic-co-glycolic acid)Polζ, Translesion DNA polymerasePTEN, Phosphatase and tensin homologPTK-1, Protein tyrosine kinase 1PTX, PaclitaxelQ, Combination efficacyRac1, Ras-related C3 botulinum toxin substrate 1RES, Reticuloendothelial systemREV, Reversionless phenotypeRGD, The tripeptide arginine−glycine−aspartic sequenceRISC, RNA Induced Silencing ComplexR, Resistance indexshRNA, Short hairpin ribonucleic acidSIP-1, Stress-induced protein 1siRNA, Small interfering ribonucleic acidSLN, Solid lipid nanoparticlesSR-BI, Scavenger receptor class B type ISSRTs, Somatostatin receptorsSTAT-3, Signal transducer and activator of transcription 3TGN, Brain targeting peptideTIMP3, Tissue inhibitor of metalloproteinase 3TLR4, Toll-like receptor 4TLS, Translesion synthesisTRAIL, Tumor necrosis factor (TNF)-related apoptosis-inducing ligandUSP9X, Ubiquitin specific peptidase 9, X-linkedVEGF, Vascular endothelial growth factorZEB, Zinc finger E-box-binding homeobox 1 transcription factor

Identifiers

PMID36147518
PMCPMC9486027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.